OncoMatch/Clinical Trials/NCT07099898
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Is NCT07099898 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Ris-Rez and Topotecan for neoplasms, lung.
Treatment: Ris-Rez · Topotecan — In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Excluded: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — es-sclc
Must have received: anti-pd-1 therapy or anti-pd-l1 therapy — es-sclc
Cannot have received: antibody-drug conjugate with topoisomerase-1 inhibitor payload
Cannot have received: b7-h3 targeted therapy
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07099898 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate with topoisomerase-1 inhibitor payload, b7-h3 targeted therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages